“…In pooled analysis of other specific complications, pEVAR was associated with a reduced risk of lymphorrhea/ seroma [11][12][13][14][15][16][20][21] compared to cEVAR (OR = 0.15, 95% CI 0.06 to -0.39, p = 0.0001). However, there were no significant differences between pEVAR and cEVAR with respect to postoperative hematoma [11][12][14][15][17][18]22,23 (OR = 0.81; 95% CI 0.49 to 1.3, p = 0.42), dissection 12,14,16,17,21,23 (OR = 0.54, 95% CI: 0.16 to 1.79, p = 0.31), femoral arterial thrombosis [11][12][13][14][15]17,[21][22] (OR = 1, 95% CI: 0.44 to 2.28, p = 0.87), nerve injury 12,14,20,21 (OR = 0.31, 95% CI: 0.09 to -1.31, p = 0.08), and access site infection 12,15,17,18,[20][21][22][23] (OR = 0.39, 95% CI: 0.14-1.07, p = 0.07).…”